Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1 - Gastrointestinal tumours, lower digestive 

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)

Date

21 Oct 2023

Session

Proffered Paper session 1 - Gastrointestinal tumours, lower digestive 

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

zhenyu lin

Citation

Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. 10.1016/S0923-7534(23)04149-2

Authors

T. Zhang1, K. Tao2, Z. lin1, P. Zhang2, Y. Yin2, P. Chi3, Y. Huang3, Y. Xiao4, Z. Sun4, X. Xu5, A. Zhang6, X. Qiu7, W. Junxin8, Y. Yuan9, Z. Wang10, X.J. Qu11, F. Zhao12, C. Ma13, F. Cheng13, Z. Hou14

Author affiliations

  • 1 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 2 Department Of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 3 Department Of Colorectal Surgery, Fujian Medical University Union Hospital, 350001 - Fuzhou/CN
  • 4 Department Of Basic Surgery, Peking Union Medical College Hospital, Beijing/CN
  • 5 Cancer Center, Renmin Hospital of Wuhan University, 430060 - Wuhan/CN
  • 6 Department Of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, 71000 - Baoding/CN
  • 7 Department Of Gastrointestinal Surgery, Zhongshan Hospital Xiamen University, 361005 - Xiamen/CN
  • 8 Radiotherapy Department Of Abdominal Tumors, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 9 Department Of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 310009 - Hangzhou/CN
  • 10 Department Of Surgical Oncology And General Surgery, The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN
  • 11 Department Of Medical Oncology, The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN
  • 12 Department Of Medical Affairs, Jiangsu Hengrui Pharmaceutical Co., Ltd., 201210 - Shanghai/CN
  • 13 Department Of Medical Affairs, Jiangsu Hengrui Pharmaceutical Co., Ltd., 201120 - Shanghai/CN
  • 14 Department Of Medical Affairs, Jiangsu Hengrui Pharmaceutical Co., Ltd., 200120 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract LBA25

Background

Based on the results of pre-clinical research and our phase II study, we conducted a randomized, multicenter, open-label phase III study to compare the efficacy and safety of short-course radiotherapy (SCRT) followed by immunochemotherapy versus long-course chemoradiotherapy (LCRT) followed by chemotherapy for perioperative treatment of locally advanced rectal cancer (LARC).

Methods

Patients (pts) with T3-4 or N+ rectal adenocarcinoma, where the lower edge of the tumor was ≤ 10 cm from the anal verge, were randomly assigned to either Arm A or B in a 1:1 ratio. Stratification was based on clinical T stage (≤ T3 vs. T4) and N stage (N0 vs. N+), and pts received SCRT or LCRT, followed by 2 cycles of camrelizumab (CAM) + CAPOX or CAPOX, respectively. Total mesorectal excision (TME) was performed subsequently, with an additional 6 cycles of CAM + CAPOX followed by CAM for up to 1 year in Arm A, and 6 cycles of CAPOX in Arm B. Primary endpoint was the independent review committee (IRC)-assessed pCR rate (ypT0N0). Secondary endpoints tested hierarchically were 3-year EFS rate and OS.

Results

Between July 2021 and March 2023, 231 pts were randomly assigned to Arm A (n=113) and Arm B (n=118). In Arm A, 112 pts received SCRT, 107 completed neoadjuvant therapy, and 104 underwent TME. In Arm B, 115 pts received LCRT, 109 completed neoadjuvant therapy, and 99 underwent TME. The IRC-assessed pCR rate in the ITT populations was significantly improved in Arm A (39.8% [95% CI 30.7-49.5]) versus Arm B (15.3% [95% CI 9.3-23.0]), with an odds ratio of 3.7 ([95% CI 2.0-6.9], p<0.001), meeting the primary endpoint. Subgroup analysis showed consistently positive results across all subgroups. In the surgical population, the R0 resection rate was 96.2% in Arm A and 97.0% in Arm B. Postoperative complications occurred in 38.1% of pts in Arm A versus 40.8% in Arm B. Grade ≥ 3 TRAEs were observed in 29.2% of pts in Arm A and 27.2% in Arm B throughout the treatment. Long-term survival outcomes are currently being monitored.

Conclusions

SCRT followed by CAM and chemotherapy demonstrated a superior pCR rate with acceptable tolerance compared to LCRT followed by chemotherapy for LARC.

Clinical trial identification

NCT04928807.

Editorial acknowledgement

Legal entity responsible for the study

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Funding

Jiangsu Hengrui Pharmaceuticals, Shanghai, China.

Disclosure

F. Zhao: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals Co., Ltd.. C. Ma: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals Co., Ltd.. F. Cheng: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals Co., Ltd.. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.